2224 related articles for article (PubMed ID: 29901697)
1. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
4. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
6. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
7. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
Hohman TJ; Bell SP; Jefferson AL;
JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
[TBL] [Abstract][Full Text] [Related]
8. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.
Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE
JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732
[TBL] [Abstract][Full Text] [Related]
9. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings.
Jack CR; Wiste HJ; Weigand SD; Knopman DS; Mielke MM; Vemuri P; Lowe V; Senjem ML; Gunter JL; Reyes D; Machulda MM; Roberts R; Petersen RC
Brain; 2015 Dec; 138(Pt 12):3747-59. PubMed ID: 26428666
[TBL] [Abstract][Full Text] [Related]
10. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.
Racine AM; Koscik RL; Berman SE; Nicholas CR; Clark LR; Okonkwo OC; Rowley HA; Asthana S; Bendlin BB; Blennow K; Zetterberg H; Gleason CE; Carlsson CM; Johnson SC
Brain; 2016 Aug; 139(Pt 8):2261-74. PubMed ID: 27324877
[TBL] [Abstract][Full Text] [Related]
11. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.
Petersen RC; Wiste HJ; Weigand SD; Rocca WA; Roberts RO; Mielke MM; Lowe VJ; Knopman DS; Pankratz VS; Machulda MM; Geda YE; Jack CR
JAMA Neurol; 2016 Jan; 73(1):85-92. PubMed ID: 26595683
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old.
Pelkmans W; Legdeur N; Ten Kate M; Barkhof F; Yaqub MM; Holstege H; van Berckel BNM; Scheltens P; van der Flier WM; Visser PJ; Tijms BM
Ann Clin Transl Neurol; 2021 Feb; 8(2):348-358. PubMed ID: 33421355
[TBL] [Abstract][Full Text] [Related]
14. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
15. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
16. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Rocca WA; Knopman DS; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Preboske GM; Pankratz VS; Vemuri P; Petersen RC
Lancet Neurol; 2014 Oct; 13(10):997-1005. PubMed ID: 25201514
[TBL] [Abstract][Full Text] [Related]
17. Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory.
Han JW; Maillard P; Harvey D; Fletcher E; Martinez O; Johnson DK; Olichney JM; Farias ST; Villeneuve S; Jagust W; Mungas D; DeCarli C
Neurology; 2020 Nov; 95(19):e2622-e2634. PubMed ID: 32732300
[TBL] [Abstract][Full Text] [Related]
18. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.
Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
JAMA Neurol; 2013 Aug; 70(8):1030-8. PubMed ID: 23797806
[TBL] [Abstract][Full Text] [Related]
19. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P
Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
